Hepatitis C Virus and Depression in Drug Users

Johnson, Mark E.; Fisher, Dennis G.; Fenaughty, Andrea; Theno, Shelley A.
May 1998
American Journal of Gastroenterology;May1998, Vol. 93 Issue 5, p785
Academic Journal
Objectives: Clinical case studies have implicated depression as a possible side-effect of interferon treatment for the Hepatitis C virus (HCV). However, because these studies generally did not include a pretreatment assessment of depression, it cannot be definitively stated whether depression is a side-effect of interferon treatment, a syndrome coexisting with HCV, or a common characteristic of individuals who are vulnerable to HCV infection. To gather more information about this issue, self-reported depressive symptomatology of drug users with HCV who have not received interferon treatment was compared to that of uninfected drug users. Methods: Subjects were 309 drug users not currently in substance abuse treatment who were participating in a National Institute on Drug Abuse project. Subjects completed the Center for Epidemiological Studies-Depression (CES-D) instrument and provided a blood sample for HCV testing. Results: Serological findings revealed that 52.4% of the subjects tested positive for HCV antibodies. Of the HCV-positive subjects, 57.2% had significant depressive symptomatology, whereas only 48.2% of the HCV-negative subjects did, for an overall rate of 52.6%. The two groups also differed on two specific dimensions of depression, with the HCV-positive group scoring lower on the Positive Affect scale and higher on the Somatic/Retarded Activity scale. Conclusions: These findings reveal high levels of depressive symptomatology among drug users, as well as the possibility of a coexisting depressive syndrome with HCV infection. These findings raise the possibility that depression associated with interferon treatment may, at least partially, be accounted for by preexisting depression. Further research is needed to determine the nature and origins of depression in individuals in treatment with interferon for HCV with specific focus placed on determining the dimensions of depression associated with HCV infection and...


Related Articles

  • Risk factors for hepatitis C virus infection among homeless adults. Nyamathi, Adeline M.; Dixon, Elizabeth L.; Robbins, Wendie; Smith, Cynthia; Wiley, Dorothy; Leake, Barbara; Longshore, Douglas; Gelberg, Lillian // JGIM: Journal of General Internal Medicine;Feb2002, Vol. 17 Issue 2, p134 

    Objective: To describe the prevalence of hepatitis C virus (HCV) infection in a sample of homeless and impoverished adults and examine risk factors for HCV infection in the overall sample and as a function of injection drug use.Design: Assays were conducted on stored...

  • Aetiology of Secondary Depression in Male Alcoholics. Roy, Alec // British Journal of Psychiatry;Dec96, Vol. 169, p753 

    Background. Secondary depression is common among primary alcoholics. However, its aetiology is poorly understood. Method. Forty men with primary alcoholism, abstinent for two weeks or more, with a secondary major depressive episode were compared with forty matched never-depressed primary...

  • Tratamiento de hepatitis C y psieosis: a propósito de dos casos clínicos. Román Avezuela, Nuria; Esteve Díaz, Nuria; del Valle Martín, María; Domarco Manrique, Leticia; Domínguez Longás, Alberto; Cabeza, Ignacio García // Revista de la Asociación Española de Neuropsiquiatría;ene-mar2014, Vol. 34 Issue 121, p135 

    Hepatitis C virus (HCV) is the principal cause of hepatic pathology. The usual treatment for chronic HCV infection is the combination of alpha pegylated interferon and ribavirine. The psychiatric adverse effects associated to this treatment are: anxiety, depression, mania, delirium and psychosis...

  • Depression within Hepatitis C virus patients: A case control study. Amal T Abd El Moez; Mokhles, Mohamed A; Allam, Enas H // Journal of Applied Sciences Research;Mar2013, Vol. 9 Issue 3, p2019 

    Background: The prevalence of depression is increased in patients with chronic hepatitis C virus (HCV) patients even in the absence of interferon (IFN) therapy. The aim of this work was to study the prevalence of depression in a cohort of Egyptian HCV naiive to treatment patients at early stage...

  • Hepatitis C Virus Infection: Immune Responsiveness and Interferon-a Treatment. Jirillo, E.; Pellegrino, N.M.; Piazzolla, G.; Caccavo, D.; Antonaci, S. // Current Pharmaceutical Design;Jan2000, Vol. 6 Issue 2, p169 

    Hepatitis C virus (HCV) is responsible for most cases of posttransfusion hepatitis and sporadic or community-acquired non-A, non-B hepatitis. Different generations of enzyme-linked immunosorbent assay have been generated for detecting antibodies to HCV epitopes. HCV-RNA quantitative analysis has...

  • Peginterferon-α.  // Reactions Weekly;3/12/2011, Issue 1342, p26 

    The article describes the case of a 67-year-old woman who developed sarcoid-related dacryoadenitis following treatment for hepatitis C virus infection, which peginterferon-α.

  • In Vivo and In Vitro Induction of MxA Protein in Peripheral Blood Mononuclear Cells from Patients Chronically Infected with Hepatitis C Virus. Fernandez, Mario; Quiroga, Juan Antonio; Martin, Julio; Herrero, Monserrat; Pardo, Margarita; Horisberger, Michel Andre; Carreno, Vicente // Journal of Infectious Diseases;8/1/99, Vol. 180 Issue 2 

    Examines the induction of MxA protein in peripheral blood mononuclear cells in patients infected with hepatitis C virus. Activation of interferon system to viral infection; Use of immunoblot assay in the detection of human MxA protein; Differences in the immunoregulatory mechanisms between...

  • Differential Effect of Interferon on Hepatitis C Virus lb Quasispecies in the Nonstructural Protein 5A Gene. Sakuma, Ikuo; Kurosaki, Masayuki; Izumi, Namiki; Marumo, Fumiaki; Sato, Chifumi // Journal of Infectious Diseases;10/1/99, Vol. 180 Issue 4, p1001 

    Investigates the close correlation between amino acid mutations in the nonstructural protein 5 of hepatitis C virus (HCV) in response to interferon therapy. Dynamic change of sensitivity region quasispecies; Absence of mutant-type quasispecies detected after therapy.

  • ATL>Changes in serum levels of hepatitis C virus genotype 1b monitored by real-time quantitative polymerase chain reaction as a predictor of long term response to interferon-α treatment. Enomoto, Masaru; Nishiguchi, Shuhei; Shiomi, Susumu; Tanaka, Motoharu; Yokogawa, Tadashi; Fukuda, Katsuhiko; Ueda, Tadashi; Tamori, Akihiro; Habu, Daiki; Takeda, Tadashi; Yano, Yoshihisa; Otani, Shuzo // American Journal of Gastroenterology;Feb2002, Vol. 97 Issue 2, p420 

    OBJECTIVE:The aim of this study was to find whether there is a relationship between the changes in the amounts of hepatitis C virus (HCV) at the start of interferon treatment and the long term response to therapy.METHODS:In 20 patients with HCV genotype 1b each given 880 MU of interferon-α,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics